What is the 13F Pro Quality Score for FULC?

13F Pro ranks Fulcrum Therapeutics, Inc. (FULC) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View FULC's current score at https://13fpro.ai/research/FULC (free sign-up required for the full ranking).

Which hedge funds own the most FULC stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of FULC include SUVRETTA CAPITAL MANAGEMENT,, RA CAPITAL MANAGEMENT, L.P., BlackRock,. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/FULC as soon as new 13F filings post.

Where does 13F Pro source FULC data?

All Fulcrum Therapeutics, Inc. fundamentals and ownership data come directly from SEC EDGAR. Fulcrum Therapeutics, Inc. files with the SEC under CIK 1680581. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is FULC in?

Fulcrum Therapeutics, Inc. (FULC) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is FULC research updated on 13F Pro?

FULC's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

Fulcrum Therapeutics, Inc.(FULC)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1680581 FULC stock profile & AI dashboard →

13F Pro Quality Score

Not in ranked universe

Pending next ranking run

This company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. Rankings refresh on Jan 1, Apr 1, Jul 1, Oct 1.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

FULC Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Fulcrum Therapeutics, Inc. (FULC), a Healthcare sector company. FULC is not currently included in 13F Pro's AI-ranked quality universe — this company passes all size and coverage filters but hasn't been included in the latest quarterly ranking run. rankings refresh on jan 1, apr 1, jul 1, oct 1. Based on the latest XBRL financial filings (Q1 2026), Fulcrum Therapeutics, Inc. reports net income of $-18.9M, free cash flow of $-18.8M. Top institutional holders of FULC by reported 13-F value include SUVRETTA CAPITAL MANAGEMENT,, RA CAPITAL MANAGEMENT, L.P., BlackRock,, based on the most recent SEC filings. FULC trades on the Nasdaq exchange and files with the SEC under CIK 1680581. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FULC daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Fulcrum Therapeutics, Inc. directly from SEC EDGAR. Fulcrum Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 3 and 40 since 2022, currently 39.6 — an improving long-term trajectory across 16 quarterly and live scoring snapshots.

Net Income

Q1 2026

$-18.9M

Free Cash Flow

Q1 2026

$-18.8M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

-100.0% YoY

$0.00FY 2025

FY21 $19.2MFY23 $2.8MFY24 $80.0MFY25 $0.00

Net Income

-669.6% YoY

$-74.9MFY 2025

FY21 $-80.8MFY23 $-97.3MFY24 $-9.7MFY25 $-74.9M

Operating Income

-287.1% YoY

$-84.8MFY 2025

FY21 $-81.1MFY23 $-110.7MFY24 $-21.9MFY25 $-84.8M

EPS (Diluted)

-637.5% YoY

$-1.18FY 2025

FY21 $-2.29FY23 $-1.59FY24 $-0.16FY25 $-1.18

Total Assets

+40.5% YoY

$366.3MFY 2025

FY21 $235.0MFY23 $257.7MFY24 $260.7MFY25 $366.3M

Op. Cash Flow

-2608.1% YoY

$-60.1MFY 2025

FY21 $-78.5MFY23 $-91.0MFY24 $-2.2MFY25 $-60.1M

Metric	FY 2025	FY 2024	FY 2023	FY 2021	FY 2019	FY 2017
Revenue	$0.00 -100.0%	$80.0M +2752.0%	$2.8M -85.4%	$19.2M	—	—
Net Income	$-74.9M -669.6%	$-9.7M +90.0%	$-97.3M -20.4%	$-80.8M +2.2%	$-82.7M	—
Operating Income	$-84.8M -287.1%	$-21.9M +80.2%	$-110.7M -36.5%	$-81.1M +3.8%	$-84.2M	—
EPS (Diluted)	$-1.18 -637.5%	$-0.16 +89.9%	$-1.59 +30.6%	$-2.29	—	—
Total Assets	$366.3M +40.5%	$260.7M +1.2%	$257.7M +9.7%	$235.0M +112.8%	$110.4M	—
Operating Cash Flow	$-60.1M -2608.1%	$-2.2M +97.6%	$-91.0M -15.9%	$-78.5M -98.8%	$-39.5M	—

AI Insight: FULC Financial Trends

A one-time $80M revenue event in Q2 2024 masked an ongoing cash-burn business; equity rebounded to $349M in Q4 2025, suggesting a capital raise.

• Revenue dropped to $0M after Q2 2024's $80M milestone, confirming that quarter was a non-recurring licensing or collaboration payment.

• Operating cash burn stabilized between -$14M and -$19M per quarter from Q3 2024 through Q1 2026, showing relatively controlled spend.

• Equity fell steadily from $274M in Q2 2024 to $198M in Q3 2025, then surged to $349M in Q4 2025, indicating a significant equity raise.

⚠ Equity declined from $349M in Q4 2025 to $333M in Q1 2026; burn rate will erode the raised capital within ~4–5 years absent new revenue.

⚠ Zero revenue for six consecutive quarters — next catalyst depends entirely on pipeline milestones or new partnership deals.

AI Insight: FULC Ratio Trends

Q2 2024 profitability spike was a one-off; ROIC has since stabilized near -26% to -27% after worsening to -44% in Q3 2025.

• Q2 2024 showed anomalous profitability — OpMargin 65.6%, ROE 81.0%, ROIC 76.7% — not repeated in any subsequent quarter.

• ROIC deteriorated from -39.1% in Q3 2024 to a trough of -44.1% in Q3 2025 before recovering to -26.6% in Q1 2026.

• ROE and ROA improved sequentially from Q3 2025 lows of -39.5% and -36.5% to -22.7% and -21.8% in Q1 2026.

⚠ OpMargin and NPM are missing for all quarters except Q2 2024, making operating efficiency trends largely unobservable.

⚠ D/E data is absent throughout; leverage structure and balance sheet risk cannot be assessed from available data.

⚠ Whether Q1 2026's return improvement continues or reverts toward Q3 2025 lows is a key inflection to monitor.

Get alerted when FULC's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for Fulcrum Therapeutics, Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of FULC

SUVRETTA CAPITAL MANAGEMENT, LLC
$50.3M6,561,111 sh
RA CAPITAL MANAGEMENT, L.P.
$46.4M6,053,960 sh
BlackRock, Inc.
$41.3M5,390,593 sh
TCG Crossover Management, LLC
$40.3M5,250,000 sh
BRAIDWELL LP
$24.0M3,134,922 sh
Nantahala Capital Management, LLC
$23.4M3,050,040 sh
VANGUARD CAPITAL MANAGEMENT LLC
$20.7M2,692,948 sh
Siren, L.L.C.
$18.0M2,350,000 sh
First Turn Management, LLC
$17.3M2,256,109 sh
abrdn plc
$17.0M2,211,953 sh

Fund	Value	Shares
SUVRETTA CAPITAL MANAGEMENT, LLC	$50.3M	6,561,111
RA CAPITAL MANAGEMENT, L.P.	$46.4M	6,053,960
BlackRock, Inc.	$41.3M	5,390,593
TCG Crossover Management, LLC	$40.3M	5,250,000
BRAIDWELL LP	$24.0M	3,134,922
Nantahala Capital Management, LLC	$23.4M	3,050,040
VANGUARD CAPITAL MANAGEMENT LLC	$20.7M	2,692,948
Siren, L.L.C.	$18.0M	2,350,000
First Turn Management, LLC	$17.3M	2,256,109
abrdn plc	$17.0M	2,211,953

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put FULC on your watchlist

Track score changes the day Fulcrum Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is FULC a good stock to buy?

13F Pro's AI-powered analysis of Fulcrum Therapeutics, Inc. (FULC) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FULC are available on the FULC stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own FULC?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FULC. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Fulcrum Therapeutics, Inc.'s investment landscape.